We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intranasal Midazolam Versus Rectal Diazepam for Treatment of Seizures

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00326612
First Posted: May 17, 2006
Last Update Posted: October 26, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Primary Children's Hospital
Information provided by (Responsible Party):
Maija Holsti, University of Utah
Results First Submitted: March 10, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Seizures
Interventions: Drug: Midazolam
Drug: Diazepam

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruited from a pediatric Neurology clinic.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Intranasal Midazolam 0.2 mg/kg Intranasal Midazolam for a seizure longer than 5 minutes
Rectal Diazepam 0.3-0.5 Rectal Diazepam for a seizure lasting longer than 5 minutes

Participant Flow:   Overall Study
    Intranasal Midazolam   Rectal Diazepam
STARTED   179   179 
COMPLETED   50   42 
NOT COMPLETED   129   137 
They did not have a seizure requiring tx                129                137 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Intranasal Midazolam 0.2 mg/kg Intranasal Midazolam for a seizure longer than 5 minutes
Rectal Diazepam 0.3-0.5 Rectal Diazepam for a seizure lasting longer than 5 minutes
Total Total of all reporting groups

Baseline Measures
   Intranasal Midazolam   Rectal Diazepam   Total 
Overall Participants Analyzed 
[Units: Participants]
 50   42   92 
Age 
[Units: Participants]
     
<=18 years   50   42   92 
Between 18 and 65 years   0   0   0 
>=65 years   0   0   0 
Age 
[Units: Years]
Mean (Standard Deviation)
 6.8  (5.0)   7.3  (4.5)   7.0  (4.8) 
Gender 
[Units: Participants]
     
Female   26   20   46 
Male   24   22   46 
Region of Enrollment 
[Units: Participants]
     
United States   50   42   92 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Length of Seizure After Study Medication Administration   [ Time Frame: 24 hours ]

2.  Secondary:   Respiratory Depression Requiring Intubation   [ Time Frame: 24 hours ]

3.  Secondary:   Number of Patients Who Needed Additional Medication to Treat the Seizure in the Emergency Department Within 24 Hours   [ Time Frame: 24 hours ]

4.  Secondary:   Number of Patients Needed to be Seen or Treated in the Emergency Department for Their Seizure and Use of Study Medication.   [ Time Frame: 24 hours ]

5.  Secondary:   Number of Patients That Were Admitted to the Hospital After Their Seizure and Use of Study Medication.   [ Time Frame: 24 hours ]

6.  Secondary:   Number of Patients Who Had a Repeat Seizure Within 12 Hours After Their Seizure Who Used Study Medication   [ Time Frame: 12 hours ]

7.  Secondary:   Respiratory Depression Requiring Oxygen at Discharge From the Emergency Department.   [ Time Frame: 24 hours ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Maija Holsti, MD, MPH
Organization: DIvision of Pediatric Emergency Medicine
phone: 801-587-7450
e-mail: maija.holsti@hsc.utah.edu


Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Maija Holsti, University of Utah
ClinicalTrials.gov Identifier: NCT00326612     History of Changes
Other Study ID Numbers: 15275
First Submitted: May 15, 2006
First Posted: May 17, 2006
Results First Submitted: March 10, 2011
Results First Posted: October 26, 2011
Last Update Posted: October 26, 2011